Program
QL2401
A development code. Also written as “QL2401 25 mg”, “QL2401 50 mg” and “QL2401 100 mg”.
Its studies are mostly in Fatty Liver, led by Qilu Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 21 open or running | phase 2since May 27, 2026 | Dec 29, 2025 | Jun 2027phase 2 · NCT07620366 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 29, 2025First study: phase 1 study in Metabolic Dysfunction-Associated Steatohepatitis(MASH)First studyNCT07331545 · 71 enrolled · China
- May 27, 2026Phase 2 study in Metabolic Dysfunction-associated Steatohepatitis (MASH)Phase 2 reachedNCT07620366 · 132 planned
Ahead
- Jun 2027Primary completion: phase 2 study in Metabolic Dysfunction-associated Steatohepatitis (MASH)NCT07620366
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07620366Metabolic Dysfunction-associated Steatohepatitis (MASH) | 2 | Not yet recruiting | Jun 2027 | 132 |
| NCT07331545Metabolic Dysfunction-Associated Steatohepatitis(MASH) · China | 1 | Completed | Jun 24, 2026 | 71 |
How it is read
Names in the registry
- “QL2401 25 mg”, 1 entry
- “QL2401 50 mg”, 1 entry
- “QL2401 100 mg”, 1 entry
- “QL2401”, 1 entry
Codes read as this program: QL2401.
Conditions, from the studies’ own filings
- Fatty Liver, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.